Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Liam G Heaney; Ratko Djukanovic; Ashley Woodcock; Samantha Walker; John G Matthews; Ian D Pavord; Peter Bradding; Robert Niven; Chris E Brightling; Rekha Chaudhuri; Joseph R Arron; David F Choy; Douglas Cowan; Adel Mansur; Andrew Menzies-Gow; Ian Adcock; Kian F Chung; Chris Corrigan; Peter Coyle; Timothy Harrison; Sebastian Johnston; Peter Howarth; James Lordan; Ian Sabroe; Jeannette Bigler; Dirk Smith; Matthew Catley; Richard May; Lisa Pierre; Chris Stevenson; Glenn Crater; Frank Keane; Richard W Costello; Val Hudson; David Supple; Tim Hardman

doi:10.1136/thoraxjnl-2015-207326

Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, Samantha Walker, John G Matthews, Ian D Pavord, Peter Bradding, Robert Niven, Chris E Brightling, Rekha Chaudhuri, Joseph R Arron, David F Choy, Douglas Cowan, Adel Mansur, Andrew Menzies-Gow, Ian Adcock, Kian F Chung, Chris Corrigan, Peter Coyle, Timothy HarrisonSebastian Johnston, Peter Howarth, James Lordan, Ian Sabroe, Jeannette Bigler, Dirk Smith, Matthew Catley, Richard May, Lisa Pierre, Chris Stevenson, Glenn Crater, Frank Keane, Richard W Costello, Val Hudson, David Supple, Tim Hardman

Research output: Contribution to journal › Review article › peer-review

81 Citations (Scopus)

889 Downloads (Pure)

Abstract

The UK Refractory Asthma Stratification Programme(RASP-UK) will explore novel biomarker stratificationstrategies in severe asthma to improve clinicalmanagement and accelerate development of newtherapies. Prior asthma mechanistic studies have notstratified on inflammatory phenotype and theunderstanding of pathophysiological mechanisms inasthma without Type 2 cytokine inflammation is limited.RASP-UK will objectively assess adherence tocorticosteroids (CS) and examine a novel compositebiomarker strategy to optimise CS dose; this will alsoaddress what proportion of patients with severe asthmahave persistent symptoms without eosinophilic airwaysinflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

Original language	English
Pages (from-to)	1587-189
Number of pages	3
Journal	Thorax
Volume	71
Issue number	2
Early online date	23 Jul 2015
DOIs	https://doi.org/10.1136/thoraxjnl-2015-207326
Publication status	Published - 23 Jul 2015

Access to Document

10.1136/thoraxjnl-2015-207326Licence: Unspecified

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Copyright the authors 2015. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Final published version, 575 KBLicence: CC BY

Liam Heaney
- l.heaneyqub.acuk
- School of Medicine, Dentistry and Biomedical Sciences - Clinical Professor
- Wellcome Wolfson Institute for Experimental Medicine
Person: Academic

Cite this

Heaney, L. G., Djukanovic, R., Woodcock, A., Walker, S., Matthews, J. G., Pavord, I. D., Bradding, P., Niven, R., Brightling, C. E., Chaudhuri, R., Arron, J. R., Choy, D. F., Cowan, D., Mansur, A., Menzies-Gow, A., Adcock, I., Chung, K. F., Corrigan, C., Coyle, P., ... Hardman, T. (2015). Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax, 71(2), 1587-189. https://doi.org/10.1136/thoraxjnl-2015-207326

@article{1bde655575d14aed89f57276892be0e0,

title = "Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)",

abstract = "The UK Refractory Asthma Stratification Programme(RASP-UK) will explore novel biomarker stratificationstrategies in severe asthma to improve clinicalmanagement and accelerate development of newtherapies. Prior asthma mechanistic studies have notstratified on inflammatory phenotype and theunderstanding of pathophysiological mechanisms inasthma without Type 2 cytokine inflammation is limited.RASP-UK will objectively assess adherence tocorticosteroids (CS) and examine a novel compositebiomarker strategy to optimise CS dose; this will alsoaddress what proportion of patients with severe asthmahave persistent symptoms without eosinophilic airwaysinflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.",

author = "Heaney, {Liam G} and Ratko Djukanovic and Ashley Woodcock and Samantha Walker and Matthews, {John G} and Pavord, {Ian D} and Peter Bradding and Robert Niven and Brightling, {Chris E} and Rekha Chaudhuri and Arron, {Joseph R} and Choy, {David F} and Douglas Cowan and Adel Mansur and Andrew Menzies-Gow and Ian Adcock and Chung, {Kian F} and Chris Corrigan and Peter Coyle and Timothy Harrison and Sebastian Johnston and Peter Howarth and James Lordan and Ian Sabroe and Jeannette Bigler and Dirk Smith and Matthew Catley and Richard May and Lisa Pierre and Chris Stevenson and Glenn Crater and Frank Keane and Costello, {Richard W} and Val Hudson and David Supple and Tim Hardman",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/",

year = "2015",

month = jul,

day = "23",

doi = "10.1136/thoraxjnl-2015-207326",

language = "English",

volume = "71",

pages = "1587--189",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "2",

}

Heaney, LG, Djukanovic, R, Woodcock, A, Walker, S, Matthews, JG, Pavord, ID, Bradding, P, Niven, R, Brightling, CE, Chaudhuri, R, Arron, JR, Choy, DF, Cowan, D, Mansur, A, Menzies-Gow, A, Adcock, I, Chung, KF, Corrigan, C, Coyle, P, Harrison, T, Johnston, S, Howarth, P, Lordan, J, Sabroe, I, Bigler, J, Smith, D, Catley, M, May, R, Pierre, L, Stevenson, C, Crater, G, Keane, F, Costello, RW, Hudson, V, Supple, D & Hardman, T 2015, 'Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)', Thorax, vol. 71, no. 2, pp. 1587-189. https://doi.org/10.1136/thoraxjnl-2015-207326

TY - JOUR

T1 - Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

AU - Heaney, Liam G

AU - Djukanovic, Ratko

AU - Woodcock, Ashley

AU - Walker, Samantha

AU - Matthews, John G

AU - Pavord, Ian D

AU - Bradding, Peter

AU - Niven, Robert

AU - Brightling, Chris E

AU - Chaudhuri, Rekha

AU - Arron, Joseph R

AU - Choy, David F

AU - Cowan, Douglas

AU - Mansur, Adel

AU - Menzies-Gow, Andrew

AU - Adcock, Ian

AU - Chung, Kian F

AU - Corrigan, Chris

AU - Coyle, Peter

AU - Harrison, Timothy

AU - Johnston, Sebastian

AU - Howarth, Peter

AU - Lordan, James

AU - Sabroe, Ian

AU - Bigler, Jeannette

AU - Smith, Dirk

AU - Catley, Matthew

AU - May, Richard

AU - Pierre, Lisa

AU - Stevenson, Chris

AU - Crater, Glenn

AU - Keane, Frank

AU - Costello, Richard W

AU - Hudson, Val

AU - Supple, David

AU - Hardman, Tim

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

PY - 2015/7/23

Y1 - 2015/7/23

N2 - The UK Refractory Asthma Stratification Programme(RASP-UK) will explore novel biomarker stratificationstrategies in severe asthma to improve clinicalmanagement and accelerate development of newtherapies. Prior asthma mechanistic studies have notstratified on inflammatory phenotype and theunderstanding of pathophysiological mechanisms inasthma without Type 2 cytokine inflammation is limited.RASP-UK will objectively assess adherence tocorticosteroids (CS) and examine a novel compositebiomarker strategy to optimise CS dose; this will alsoaddress what proportion of patients with severe asthmahave persistent symptoms without eosinophilic airwaysinflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

AB - The UK Refractory Asthma Stratification Programme(RASP-UK) will explore novel biomarker stratificationstrategies in severe asthma to improve clinicalmanagement and accelerate development of newtherapies. Prior asthma mechanistic studies have notstratified on inflammatory phenotype and theunderstanding of pathophysiological mechanisms inasthma without Type 2 cytokine inflammation is limited.RASP-UK will objectively assess adherence tocorticosteroids (CS) and examine a novel compositebiomarker strategy to optimise CS dose; this will alsoaddress what proportion of patients with severe asthmahave persistent symptoms without eosinophilic airwaysinflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

U2 - 10.1136/thoraxjnl-2015-207326

DO - 10.1136/thoraxjnl-2015-207326

M3 - Review article

C2 - 26205878

SN - 0040-6376

VL - 71

SP - 1587

EP - 1189

JO - Thorax

JF - Thorax

IS - 2

ER -

Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Abstract

Access to Document

Fingerprint

Profiles

Liam Heaney

Cite this